Genitourinary Drugs Market By Therapeutic Area (Genitourinary Oncology, Urinary Tract Infections and GU Anti-Infectives, Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, Overactive Bladder and Urinary Incontinence, Erectile Dysfunction, Infertility and Reproductive Health, Genitourinary Syndrome of Menopause, Sexually Transmitted Infections, Other Genitourinary Conditions); By Drug Class (Antibiotics and Anti-Infectives, Hormonal and Androgen-Pathway Therapies, Immunotherapies and Targeted Oncology Drugs, Intravesical Agents, Alpha Blockers, 5-Alpha-Reductase Inhibitors, PDE5 Inhibitors, Antimuscarinics, Beta-3 Adrenergic Agonists, Fertility Hormones and Adjunctive Therapies, Other Drug Classes); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Genitourinary Drugs Market: GU Oncology Innovation, UTI Antibiotic Renewal, Chronic Urology Demand, and Sexual-Health Therapeutics Expand a Broad Specialty Drug Market

The Global Genitourinary Drugs Market will witness a robust 1.27% CAGR, valued at USD 31.2 billion in 2025, projected to reach 34.1 billion by 2032, according to Strategic Market Research.

 

The Genitourinary Drugs Market is becoming a more strategic healthcare category as urology, oncology, infectious disease, reproductive medicine, and sexual health increasingly overlap in clinical practice and pharmaceutical development. The market covers drugs used for genitourinary cancers, urinary tract infections, overactive bladder, urinary incontinence, benign prostatic hyperplasia, erectile dysfunction, genitourinary syndrome of menopause, infertility, selected sexually transmitted infections, and intravesical bladder therapies. Commercial momentum is primarily driven by four key demand areas: high-value genitourinary oncology, renewed oral antibiotic development for urinary tract infections and urogenital gonorrhea, age-related chronic urologic treatment needs, and fertility and sexual health therapies.

 

The underlying disease burden associated with this market is notably broad. UTI episodes reached an estimated 4.49 billion globally in 2021, increasing 66.45% from 1990. In the United States, UTIs account for about 10 million annual physician-office encounters, making them one of the most common outpatient infection categories. At the chronic-care end, NIDDK estimates that benign prostatic hyperplasia affects 5%–6% of men aged 40–64 and 29%–33% of men aged 65 and older, while overactive bladder prevalence ranges from 7%–27% in men and 9%–43% in women. Sexual-health and reproductive categories add another high-volume layer: NIDDK estimates 30 million to 50 million U.S. men have erectile dysfunction, and WHO estimates that about 1 in 6 adults worldwide experience infertility during their lifetime.

 

UTI and GU Anti-Infectives Are Re-Entering an Innovation Cycle

UTI treatment is one of the most active drug-development areas within the Genitourinary Drugs Market because high case volume is now colliding with antimicrobial resistance. WHO reported that 1 in 5 E. coli urinary tract infections in 2020 showed reduced susceptibility to common antibiotics such as ampicillin, co-trimoxazole, and fluoroquinolones. This creates demand for new oral agents, narrower-spectrum options, and products that reduce avoidable IV therapy or hospitalization.

Recent FDA approvals show that the GU anti-infective segment is no longer limited to older generics. Pivya, or pivmecillinam, was approved by the FDA in 2024 for uncomplicated UTIs in adult women caused by susceptible E. coli, Proteus mirabilis, and Staphylococcus saprophyticus. Iterum’s Orlynvah, a combination of sulopenem etzadroxil and probenecid, was approved in 2024 for adult women with uncomplicated UTIs who have limited or no alternative oral antibacterial options. GSK’s Blujepa, or gepotidacin, was approved in 2025 for uncomplicated UTIs in female adults and pediatric patients aged 12 years and older weighing at least 40 kg. Utebzi, or tebipenem pivoxil, was then approved in June 2026 as the first oral carbapenem therapy in the United States for complicated UTIs, including pyelonephritis, in adults with limited or no alternative oral options.

These approvals are commercially significant as they restore momentum in the oral genitourinary antibiotic segment following a prolonged period of limited innovation. They also create a more segmented market: uncomplicated female UTIs, resistant or limited-option uUTIs, complicated UTIs requiring carbapenem-level coverage, and outpatient step-down therapy after hospital treatment. GSK is now a stronger GU anti-infective player through Blujepa and Utebzi, while Utility Therapeutics, Iterum, and Spero-linked/GSK assets reflect renewed commercial interest in UTI treatment.

 

Urogenital Gonorrhea Is Becoming a Drug-Resistance Market

The STI segment is gaining relevance because resistant Neisseria gonorrhoeae has reduced confidence in traditional treatment pathways. CDC reported more than 2.2 million U.S. cases of chlamydia, gonorrhea, and syphilis in 2024, including 543,000 gonorrhea cases. Although combined STI cases declined 9% from 2023, the overall burden remained 13% higher than a decade earlier. Globally, WHO has estimated 82 million new gonorrhea infections annually, making urogenital gonorrhea a major target for oral treatment innovation.

Two December 2025 FDA approvals changed the competitive landscape. Nuzolvence, or zoliflodacin, developed by Innoviva Specialty Therapeutics in partnership with GARDP, was approved as a single-dose oral therapy for uncomplicated urogenital gonorrhea in adults and adolescents. Blujepa also received FDA approval as an oral option for uncomplicated urogenital gonorrhea in patients 12 years and older with limited or no alternative treatment options. These approvals are commercially important because gonorrhea treatment has relied heavily on injectable ceftriaxone, while resistance pressure has increased the need for new oral classes.

For the GU Drugs Market, this creates a distinct anti-infective subsegment where value is tied to resistance management, access, public-health procurement, and stewardship rather than high-volume chronic use. Innoviva, GARDP, and GSK are the most visible companies in this newly active oral gonorrhea treatment space.

 

GU Oncology Is the Highest-Value Innovation Engine

GU oncology is the most commercially intensive part of the market because it includes prostate, bladder, kidney, and testicular cancers. GLOBOCAN 2022 estimated about 1.47 million new prostate cancer cases and 397,430 deaths worldwide; 614,298 bladder cancer cases and 220,596 deaths; 434,840 kidney cancer cases and 155,953 deaths; and 72,040 testicular cancer cases and 9,068 deaths. Combined, these four major GU cancers accounted for roughly 2.59 million new cases and about 783,000 deaths in 2022.

The U.S. market is particularly important because GU cancers occupy several top incidence categories. SEER/ACS 2026 estimates include 333,830 new prostate cancer cases and 36,320 deaths, 84,530 bladder cancer cases and 17,870 deaths, 80,450 kidney and renal pelvis cancer cases and 15,160 deaths, and about 9,810 testicular cancer cases and 630 deaths. This gives the United States more than half a million expected new cases across these four GU cancers in 2026, creating strong demand for androgen-receptor pathway inhibitors, ADT combinations, immune checkpoint inhibitors, antibody-drug conjugates, HIF-2α inhibitors, intravesical therapies, radiopharmaceuticals, and chemotherapy.

Recent approvals show how quickly the GU oncology segment is changing. In kidney cancer, FDA approved Merck’s belzutifan in combination with pembrolizumab in June 2026 for adjuvant treatment of renal cell carcinoma with a clear-cell component at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions. In prostate cancer, FDA approved AstraZeneca’s capivasertib with abiraterone and prednisone in June 2026 for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. This is important because it links prostate cancer treatment more directly to biomarker-defined PTEN loss and companion diagnostic use.

Bladder cancer has seen the most concentrated regulatory activity. UroGen’s Zusduri, a mitomycin intravesical solution using RTGel technology, was approved in June 2025 for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Johnson & Johnson’s Inlexzo, a gemcitabine intravesical system formerly known as TAR-200, was approved in September 2025 for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors. In 2026, FDA approved atezolizumab for adjuvant treatment of muscle-invasive bladder cancer in patients with circulating tumor DNA molecular residual disease, and durvalumab with BCG for BCG-naïve high-risk NMIBC. These approvals show that bladder cancer drugs are moving into earlier disease, intravesical sustained delivery, MRD-guided treatment, and immunotherapy-plus-BCG combinations.

The competitive landscape is led by Merck, AstraZeneca, Roche/Genentech, Johnson & Johnson, UroGen, Pfizer/Astellas, Bristol Myers Squibb, Exelixis, Eisai, Bayer, Novartis, and several focused biotech developers. Differentiation is no longer based only on late-line metastatic therapy. Companies are moving into adjuvant settings, office-based intravesical delivery, BCG-unresponsive disease, biomarker-defined prostate cancer, and renal cancer recurrence prevention.

 

Chronic Urology Prescribing Is Driven by Ageing Male and Female Populations

BPH, LUTS, overactive bladder, urinary incontinence, and ED form the largest chronic-use segment by prescription breadth. BPH drives demand for alpha blockers such as tamsulosin, 5-alpha-reductase inhibitors such as finasteride and dutasteride, PDE5 inhibitors such as tadalafil, and combination regimens. The commercial base is ageing-linked: BPH prevalence rises from 5%–6% in men aged 40–64 to 29%–33% in men aged 65 and older.

Overactive bladder and urinary incontinence support demand for antimuscarinics, beta-3 adrenergic agonists, estrogen-related urogenital therapies in selected women, and medication sequences that balance symptom control with tolerability. AUA/SUFU reports OAB prevalence of 7%–27% in men and 9%–43% in women, while NIDDK reports that approximately half of women experience urinary incontinence and as many as 1 in 3 men over 65 have accidental urine loss. This creates strong volume potential, but adherence and persistence remain difficult because anticholinergic adverse effects, cost, and modest perceived benefit can limit long-term use.

ED remains a large men’s-health segment anchored by generic PDE5 inhibitors. NIDDK estimates 30 million to 50 million U.S. men have ED, with prevalence rising from about 40% at age 40 to 70% by age 70. Generic sildenafil and tadalafil dominate access, while branded and digital-health channels compete on convenience, discretion, bundling with testosterone or men’s health services, and online pharmacy fulfillment.

 

Reproductive and Women’s GU Health Add High-Need Adjacent Demand

Infertility and genitourinary syndrome of menopause expand the market beyond classic urology. WHO estimates that 17.5% of adults, or roughly 1 in 6 worldwide, experience infertility during their lifetime. This supports demand for ovulation induction drugs, gonadotropins, hormonal therapies, luteal-phase support, ART adjuncts, and reproductive endocrinology drug protocols. The commercial challenge is not prevalence; it is access, affordability, insurance coverage, and clinic capacity.

Genitourinary syndrome of menopause is another under-addressed women’s GU drug category. Published reviews estimate that GSM affects 27%–84% of postmenopausal women, depending on population and symptom definition. Drug demand includes vaginal estrogen products, vaginal DHEA, oral ospemifene, moisturizers, and non-hormonal or hormone-sparing options for women who cannot or do not want estrogen therapy. This segment is clinically relevant because GSM overlaps with urinary symptoms, recurrent UTIs, sexual pain, and quality-of-life impairment, but treatment remains underused due to patient reluctance, clinician underdiagnosis, and safety concerns in women with hormone-sensitive cancer histories.

 

HIV and Sexual-Health Antivirals Are Adjacent, Not Core GU Drugs

HIV antiretrovirals, PrEP, and PEP should be treated as adjacent sexual-health therapeutics rather than core genitourinary tract agents unless the report scope explicitly includes STI/HIV prescribing channels. WHO reported that 31.6 million people, or 77% of people living with HIV globally, were receiving antiretroviral therapy in 2024, and 73% were virally suppressed. This scale is important for sexual-health infrastructure, pharmacy distribution, prevention programs, and long-acting therapy adoption, but it should not be merged directly into the narrower urology drug market without clear scope definition.

 

Regional Outlook

North America remains the highest-value regional market, driven by the United States, which concentrates both premium genitourinary oncology launches and high-volume urology prescribing. In 2026, the U.S. is expected to record 333,830 prostate cancer cases, 84,530 bladder cancer cases, 80,450 kidney and renal pelvis cancer cases, and approximately 9,810 testicular cancer cases, positioning genitourinary malignancies among the largest oncology treatment pools. The infectious disease segment also contributes meaningfully to market activity, with urinary tract infections accounting for nearly 10 million physician-office encounters annually, while CDC data reported over 2.2 million combined cases of chlamydia, gonorrhea, and syphilis in 2024, including 543,000 gonorrhea cases. This reinforces the U.S. role as the primary launch market for premium genitourinary therapies across intravesical bladder cancer treatments, renal cancer combination regimens, biomarker-guided prostate cancer therapies, novel oral antibiotics for urinary tract infections, and oral therapies for urogenital gonorrhea. Recent FDA approvals and regulatory activity across agents including Zusduri, Inlexzo, belzutifan-pembrolizumab, capivasertib-abiraterone-prednisone, MRD-guided atezolizumab bladder cancer therapy, durvalumab plus BCG, Pivya, Orlynvah, Blujepa, Nuzolvence, and Utebzi further underscore North America’s role in setting both the regulatory and commercial trajectory for genitourinary oncology and anti-infective markets.

Europe represents a mature yet high-burden market, where oncology prevalence, rising sexually transmitted infections, and ageing-related urological prescribing patterns collectively sustain long-term demand. GLOBOCAN estimated approximately 1.92 million five-year prevalent prostate cancer cases in Europe in 2022, positioning prostate cancer as a significant long-term treatment and surveillance population. The region is also experiencing a rising genitourinary infection and sexual health burden, with ECDC reporting 106,331 gonorrhea cases in the EU/EEA in 2024, reflecting a 303% increase since 2015, alongside 45,577 syphilis cases and 213,443 chlamydia cases, the latter remaining the most frequently reported STI. This supports continued demand for antimicrobial therapies, diagnostic-linked treatment pathways, and resistance-aware prescribing strategies. Chronic urology demand is structurally reinforced by an ageing population, contributing to sustained utilization of therapies for benign prostatic hyperplasia, overactive bladder, urinary incontinence, erectile dysfunction, and genitourinary syndrome of menopause. However, market access remains more evidence-driven than in the United States, with premium urology and oncology therapies subject to health technology assessment review, survival and outcomes-based evaluation, biomarker-defined eligibility criteria, antimicrobial stewardship controls, and national budget-impact constraints.

Asia Pacific is the largest long-term volume opportunity because the region combines ageing, rising cancer incidence, high infection burden, fertility demand, and expanding specialist access. China alone reported approximately 266,887 incident GU cancer cases and 108,589 deaths in 2021 across bladder, kidney, prostate, and testicular cancers, making it one of the most important country markets for GU oncology. Southeast Asia is also showing rapid growth: GU cancer incidence increased from 16,947 cases in 1990 to 74,556 in 2021, while mortality increased from 20,500 to 61,113 over the same period. Kidney cancer showed the fastest rise in the region, while prostate cancer remains a major driver of male GU oncology demand. India adds a large antibiotic and generic-urology base, rising private urology care, increasing fertility-treatment demand, and strong domestic drug manufacturing. Japan, South Korea, Singapore, and Australia remain premium markets where ageing, reimbursement, clinical-trial access, and specialist urology-oncology infrastructure support adoption of advanced GU cancer drugs, beta-3 agonists, fertility therapies, and newer GU anti-infectives.

 

Competitive Direction

The Genitourinary Drugs Market is increasingly split between high-value specialty innovation and high-volume generic chronic care. GU oncology is innovation-led, with Merck, AstraZeneca, Roche/Genentech, Johnson & Johnson, UroGen, Pfizer/Astellas, Bristol Myers Squibb, Bayer, Novartis, Exelixis, and Eisai competing across renal, bladder, and prostate cancer. GU infections are being reshaped by GSK, Innoviva/GARDP, Iterum, Utility Therapeutics, and Spero/GSK through new oral options for uUTI, cUTI, and urogenital gonorrhea.

Chronic urology is more generic-driven, with tamsulosin, finasteride, dutasteride, tadalafil, sildenafil, oxybutynin, tolterodine, solifenacin, mirabegron, vibegron, and combination regimens shaping prescription volume. Women’s GU health and fertility drugs are more fragmented, involving hormone products, SERMs, vaginal DHEA, gonadotropins, IVF-adjacent drugs, and reproductive endocrinology protocols.

 

Analyst Insight

The Genitourinary Drugs Market should be viewed as a multi-engine market rather than a single therapeutic category. High-volume demand comes from UTIs, BPH, OAB, urinary incontinence, ED, infertility, and menopause-related GU symptoms. High-value growth comes from GU oncology, antibiotic-resistant urogenital infections, intravesical drug delivery, and biomarker-defined therapy.

The strongest near-term momentum is emerging across multiple areas. Bladder cancer is transitioning from repeated local procedures and BCG dependence toward intravesical delivery systems, immunotherapy combinations, and MRD-guided treatment strategies. UTI and gonorrhea therapy are experiencing a renewed cycle of oral antibiotic innovation, driven by rising resistance and outpatient care economics. Ageing-related chronic urology continues to support high prescription volumes, although most revenue expansion is expected to be driven by differentiated therapies rather than established generics.

The companies best positioned in this market are those that can connect drug innovation with a specific treatment bottleneck: avoiding cystectomy, replacing repeat TURBT, moving infection treatment out of the hospital, addressing resistant pathogens, reducing recurrence, improving chronic symptom control, or selecting oncology patients by biomarker. The market is broad, but the commercial advantage is increasingly narrow and evidence-specific.

 

Genitourinary Drugs Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 31.2 Billion
Revenue Forecast in 2032	USD 34.1 Billion
Overall Growth Rate	CAGR of 1.27%
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million and CAGR (2026–2032)
Segmentation	By Therapeutic Area, By Drug Class, By Distribution Channel, and By Geography
By Therapeutic Area	Genitourinary Oncology; Urinary Tract Infections and GU Anti-Infectives; Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms; Overactive Bladder and Urinary Incontinence; Erectile Dysfunction; Infertility and Reproductive Health; Genitourinary Syndrome of Menopause; Sexually Transmitted Infections; Other Genitourinary Conditions
By Drug Class	Antibiotics and Anti-Infectives; Hormonal and Androgen-Pathway Therapies; Immunotherapies and Targeted Oncology Drugs; Intravesical Agents; Alpha Blockers; 5-Alpha-Reductase Inhibitors; PDE5 Inhibitors; Antimuscarinics; Beta-3 Adrenergic Agonists; Fertility Hormones and Adjunctive Therapies; Other Drug Classes
By Distribution Channel	Hospital Pharmacies; Retail Pharmacies and Drug Stores; Online Pharmacies
By Region	North America; Europe; Asia-Pacific; Latin America; Middle East and Africa
Country Scope	United States, Canada, Mexico, United Kingdom, Germany, France, Italy, Spain, China, India, Japan, South Korea, Australia, Brazil, Argentina, Saudi Arabia, United Arab Emirates, and South Africa
Market Drivers	Rising demand for high-value therapies across prostate, bladder, kidney, and testicular cancers; renewal of oral antibiotic pipelines for urinary tract infections and drug-resistant urogenital infections; expanding chronic treatment demand linked to ageing, BPH, overactive bladder, urinary incontinence, and erectile dysfunction; increasing use of fertility and women’s genitourinary health therapies
Customization Option	Available upon request